AstraZeneca in coronary diseases research deal with Kuwait University

11 October 2011

Kuwait University revealed that it has signed a scientific cooperation agreement with Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) local subsidiary to conduct research on coronary arteries diseases in several Gulf Arab states, reports the Kuwait news agency KUNA.

"This agreement comes within the framework of the University commitment to contribute to the development of knowledge society through a series of academic research programs," University Chancellor Abdel-Latif Al-Bader said in press statements following the signing ceremony.

Company will finance the research

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK